Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

In the US Spinraza costs $750,000 for the first year, and $375,000 thereafter, although in the UK the list price is slightly lower at around £450,000 ($581,000) for the first year.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Ionis has six marketed medicines to treat serious diseases: TRYNGOLZA, which was approved in December last year, to treat adults living with familial chylomicronemia syndrome (FCS) SPINRAZA ...

Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri ...

Spinraza, a treatment for spinal muscular atrophy, is expected to slightly exceed expectations, while multiple sclerosis treatments Avonex and Tysabri may underperform. Biogen’s Alzheimer’s ...

TORONTO, April 22, 2025 /CNW/ - DRI Healthcare Trust (DHT.U:CA) (the "Trust"), a global leader in providing financing to advance innovation in the life sciences industry, announces that it will ...

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease ...